» Articles » PMID: 36430906

Recent Advances in Nanomaterials for Asthma Treatment

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Nov 26
PMID 36430906
Authors
Affiliations
Soon will be listed here.
Abstract

Asthma is a chronic airway inflammatory disease with complex mechanisms, and these patients often encounter difficulties in their treatment course due to the heterogeneity of the disease. Currently, clinical treatments for asthma are mainly based on glucocorticoid-based combination drug therapy; however, glucocorticoid resistance and multiple side effects, as well as the occurrence of poor drug delivery, require the development of more promising treatments. Nanotechnology is an emerging technology that has been extensively researched in the medical field. Several studies have shown that drug delivery systems could significantly improve the targeting, reduce toxicity and improve the bioavailability of drugs. The use of multiple nanoparticle delivery strategies could improve the therapeutic efficacy of drugs compared to traditional delivery methods. Herein, the authors presented the mechanisms of asthma development and current therapeutic methods. Furthermore, the design and synthesis of different types of nanomaterials and micromaterials for asthma therapy are reviewed, including polymetric nanomaterials, solid lipid nanomaterials, cell membranes-based nanomaterials, and metal nanomaterials. Finally, the challenges and future perspectives of these nanomaterials are discussed to provide guidance for further research directions and hopefully promote the clinical application of nanotherapeutics in asthma treatment.

Citing Articles

Innovative approaches to asthma treatment: harnessing nanoparticle technology.

Goswami V, Sodhi K, Singh C Discov Nano. 2025; 20(1):21.

PMID: 39922940 PMC: 11807046. DOI: 10.1186/s11671-025-04211-z.


Nanoparticles to target asthma.

Hamrick S, Thompson M, Rotello V, Prakash Y, Pabelick C Am J Physiol Lung Cell Mol Physiol. 2024; 327(6):L964-L971.

PMID: 39470612 PMC: 11684954. DOI: 10.1152/ajplung.00248.2024.


Application of nano- and micro-particle-based approaches for selected bronchodilators in management of asthma.

Singh S, Aparna , Sharma N, Gupta J, Kyada A, Nathiya D 3 Biotech. 2024; 14(9):208.

PMID: 39184911 PMC: 11343956. DOI: 10.1007/s13205-024-04051-1.


Preparation of Budesonide-Loaded Liposomal Nanoparticles for Pulmonary Delivery and Their Therapeutic Effect in OVA-Induced Asthma in Mice.

Zuo X, Gu Y, Guo X, Zheng W, Zheng H, An Y Int J Nanomedicine. 2024; 19:673-688.

PMID: 38283200 PMC: 10811423. DOI: 10.2147/IJN.S441345.


Circular RNA vaccine in disease prevention and treatment.

Niu D, Wu Y, Lian J Signal Transduct Target Ther. 2023; 8(1):341.

PMID: 37691066 PMC: 10493228. DOI: 10.1038/s41392-023-01561-x.


References
1.
Thangam E, Angel Jemima E, Singh H, Baig M, Khan M, Mathias C . The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. Front Immunol. 2018; 9:1873. PMC: 6099187. DOI: 10.3389/fimmu.2018.01873. View

2.
El-Hammadi M, Delgado A, Melguizo C, Prados J, Arias J . Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm. 2016; 516(1-2):61-70. DOI: 10.1016/j.ijpharm.2016.11.012. View

3.
Adhikari H, Nath Yadav P . Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action. Int J Biomater. 2019; 2018:2952085. PMC: 6332982. DOI: 10.1155/2018/2952085. View

4.
Reshma V, Syama S, Sruthi S, Reshma S, Remya N, Valappil Mohanan P . Engineered Nanoparticles with Antimicrobial Property. Curr Drug Metab. 2017; 18(11):1040-1054. DOI: 10.2174/1389200218666170925122201. View

5.
Garcia-Fernandez A, Sancenon F, Martinez-Manez R . Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021; 177:113953. DOI: 10.1016/j.addr.2021.113953. View